References
- Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar 1 disorders in a general population. Arch Gen Psychiatry 2007;64:19-28
- Cheniaux E, Landeira-Fernandez J, Telles LL, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affective Disord 2008;106:209-17
- Peralta V, Cuesta MJ. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach. J Affective Disord 2008;108:71-86
- Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv 2009;60:210-16
- Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. J Clin Psychiatry 2010;71(2 Suppl):14-19
- Karve S, Markowitz M, Fu DJ, et al. Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. Appl Health Econ Health Policy 2014;12:335-46
- Lake CR, Hurwitz N. Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease—there is no schizoaffective disorder. Curr Opin Psychiatry 2007;20:365-79
- Murru A, Pacchiarotti I, Amann BL, et al. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord 2013;151:1003-8
- Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11
- Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of the literature. J Behav Med 2008;31:213-24
- Janssen Scientific Affairs. Clinical Study Report. A randomized, double-blind, placebo-controlled, parallel-group study of paliperidone palmitate evaluating time to relapse in subjects with schizoaffective disorder (PRIME). Data on File. Janssen Scientific Affairs, LLC, Raritan, NJ 2014
- Fu DJ, Turkoz I, Simonson BR, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry 2015;76:253-62
- Janssen Scientific Affairs. Invega Sustenna Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2014
- Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ 2013;16:1290-9
- U.S. Department of Health & Human Services. Medical Expenditure Panel Survey. Emergency Room Services. Rockville, MD: US Department of Health & Human Services, 2014 http://meps.ahrq.gov/mepsweb/data_stats/download_data_files_detail.jsp?cboPufNumber=HC-135E. Accessed September 30, 2014
- Centers for Medicare and Medicaid Services. Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing. Baltimore, MD: Centers for Medicare and Medicaid Services, http://www.medicarepaymentandreimbursement.com/p/medicar-fee-schedule-update.html. Accessed September 30, 2014
- U.S. Department of Labor. Consumer Price Index December 2014. USDL-14-1711. Washington DC: Bureau of Labor Statistics U.S. Department of Labor, http://www.bls.gov/news.release/pdf/cpi.pdf. Accessed September 30, 2014
- Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 2012;15:776-85
- Sun F, Stock EM, Copeland LA, et al. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am J Health Syst Pharm 2014;71:728-38
- Lochmann van Bennekorn MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013;27:327-36
- Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527-42